Aequus and Camargo Prepare for Meeting with FDA to Advance Anti-Nausea Patch

Aequus Pharmaceuticals (TSXV: AQS) a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced plans to advance its transdermal patch for pregnancy-related anti-nausea, AQS1303, following positive results from the proof of concept study completed in 2017.
As quoted in the press release:

“We feel very strongly about the need for this program and are delighted to see its continued progress,” said Anne Stevens, COO and Director of Aequus. “We expect a meeting with the FDA in the second quarter of this year and anticipate it will provide clarity on the requirements for AQS1303 in order to achieve FDA approval under 505(b)(2).”

Click here to read the full press release.